Palvella Therapeutics (NASDAQ:PVLA) COO Sells $476,360.46 in Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total transaction of $476,360.46. Following the completion of the transaction, the chief operating officer directly owned 2,154 shares in the company, valued at $238,512.42. This trade represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Palvella Therapeutics Trading Up 5.1%

NASDAQ:PVLA traded up $5.74 during midday trading on Monday, hitting $118.84. 231,409 shares of the company were exchanged, compared to its average volume of 279,634. Palvella Therapeutics, Inc. has a fifty-two week low of $20.35 and a fifty-two week high of $151.18. The company has a market capitalization of $1.70 billion, a PE ratio of -28.50 and a beta of -0.14. The company has a fifty day simple moving average of $118.63 and a 200 day simple moving average of $109.05.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.30). As a group, equities research analysts expect that Palvella Therapeutics, Inc. will post -5.26 EPS for the current year.

Hedge Funds Weigh In On Palvella Therapeutics

Several institutional investors have recently bought and sold shares of the company. KBC Group NV acquired a new position in shares of Palvella Therapeutics during the first quarter worth about $28,000. Group One Trading LLC lifted its position in Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares during the period. Russell Investments Group Ltd. acquired a new stake in Palvella Therapeutics in the third quarter valued at about $36,000. JPMorgan Chase & Co. boosted its holdings in Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Palvella Therapeutics in the 2nd quarter valued at approximately $85,000. 40.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PVLA has been the topic of several research analyst reports. BTIG Research lifted their price target on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Wall Street Zen downgraded Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Stifel Nicolaus set a $250.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. Truist Financial set a $210.00 price target on Palvella Therapeutics in a report on Tuesday, February 24th. Finally, Chardan Capital restated a “buy” rating and issued a $240.00 price target on shares of Palvella Therapeutics in a research report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.